Načítá se...
SUN-170 Development of Type 1 Diabetes Mellitus on Immune Checkpoint Inhibitor
Introduction: Immune checkpoint inhibitors (ICPi) are used to augment the immune response and have led to improved outcomes in various malignancies. With this enhanced immunologic response comes a spectrum of side effects, known as immune-related adverse events (iRAEs). These are most commonly derma...
Uloženo v:
| Vydáno v: | J Endocr Soc |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Endocrine Society
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553242/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-170 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|